Other Cancer Immunotherapy

FDA-approved and clinical trial options for cancer immunotherapy have never been more abundant in the United States.  

What about other cancer immunotherapy in foreign countries, for those who have exhausted their options in the United States?  Unlike many alternative cancer therapies, the first and arguably most successful cancer therapy ever developed in the USA, Coley fluid, is still largely unknown to the American public.  

Other cancer immunotherapy options (such as BCG vaccine, Coley fluid, and dendritic cell vaccines) may be pursued in clinics in Japan, Germany, Mexico, and other countries.  All of them have a surprisingly good track-record of success.

In this riveting documentary, survivors of advanced cancer show their medical scans and records, and demand that the US government bring back Coley fluid, the 120 year old fever therapy that cured them.

Cancer Survivors USA - a road trip and an open letter to Senator Tom Harkin from Gar Hildenbrand on Vimeo.

Below, Dr. Ralph Moss, alternative cancer therapy expert, presents a brief history of Coley’s fever therapy and its inception at Sloan-Kettering. 

Recently Dr. Lloyd Old conducted a small clinical trial of Coley fluid at Sloan-Kettering where it had been invented nearly 120 years prior.  The trial was published in 2012, only a few months after Dr. Old’s own death from cancer.

The stunning conclusion of the trial was that Coley’s therapy "can lead to a massive induction of immunoregulatory cytokines that may be involved in inducing tumor regressions."

This portion of the website is still under development.  For those researching immunotherapy options available in Mexico, see CHIPSA Hospital, San Diego Clinic, and Issels.  All are based in Tijuana, Mexico and offer some combination of Coley fluid, BCG vaccine, and dendritic cell vaccines.

Return to Home Page

Coley Fluid

Autologous Dendritic Cell Vaccine



Saving Your Tumor for a Personalized Dendritic Cell Vaccine

Saving Your Tumor for Chemosensitivity Testing


Popular Articles and Books

Hot, Toxic, and Healing.  New Scientist: 4 January 2014.

Sarah DeWeert.  Bacteriology: a Caring Culture.  Nature: 504, S4-S5. 18 Dec. 2013. doi:10.1038/504S4a

Robert Matthews.  Pyrotherapy: fever as cure.  New Scientist: 31 July 2010.

U. Hobohm. 2009. Healing Heat: Harnessing Infection to Fight Cancer.  American Scientist 97: 34-41. 

A Commotion in the Blood: Life, Death, and the Immune System, by Stephan S. Hall.  

Spontaneous Regression: Cancer and the Immune System, by Donald H. MacAdam.  

Professional Interviews and Presentations

Interview with Don MacAdam,  (audio interview with Don MacAdam, CEO of MBVax Bioscience, on The People's Pharmacy)

Coley's Toxin, Cancer, and Immunology (audio interview with Polly Matzinger, NIH immunologist, on The People's Pharmacy)   

Peer Reviewed Articles (most recent first)

C. Maletzki, M. Linnebacher, R. Savai, U. Hobohm. 2013. Mistletoe lectin has a shiga toxin-like structure and should be combined with other Toll-like receptor ligands in cancer therapy.  Cancer Immunol Immunother 62:1283–1292. DOI 10.1007/s00262-013-1455-1

Gunver S. Kienle. 2012. Fever in Cancer Treatment: Coley's Therapy and Epidemiologic Observations. Glob Adv Health Med 1(1): 92-100. doi:  10.7453/gahmj.2012.1.1.016 

Julia Karbach, Antje Neumann, Kathrin Brand, et al. 2012. Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity. Clin Cancer Res 18:5449-5459.  doi:10.1158/1078-0432.CCR-12-1116

Nayla S. Al-Akl, Farah Khaliefeh, Alexander M. 2012. The effect of the supernatant of Coley's Mixed Bacterial Toxin (MBT) and Bacterial Lipopolysaccharide (LPS) on Serum Levels of TNF-alpha, IL-12 and VEGF in Mice. IOSR Journal of Pharmacy 2(2) pp: 210-214. 

C. Maletzski, U. Klier, W. Obst, B. Kreikemeyer, M. Linnebaker. 2012. Re-evaluating the Concept of Treating Experimental Tumors With a Mixed Bacterial Vaccine: Coley's Toxin. Clin Dev Immunol: 230625. doi:  10.1155/2012/230625

Thomas Jessy. 2011. Immunity Over Inability: The Spontaneous Regression of Cancer.  J Nat Sci Biol Med. 2(1): 43–49. doi:  10.4103/0976-9668.82318

William K. Decker, Amar Safdar. 2009. Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited. Cytokine and Growth Factor Reviews 20(4):271-81. doi: 10.1016/j.cytogfr.2009.07.004. 

U. Hobohm. 2009. Toward general prophylactic cancer vaccination. BioEssays 31:1071–1079. DOI 10.1002/bies.200900025

Uwe Hobohm, John L Stanford, John M. Grange. 2008. Pattern-Associated Molecular Pattern (PAMP) in Cancer Immunotherapy. Crit Rev Immunol 28(2): 95-107.

Edward McCarthy. 2006. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthopedic Journal 26: 154-158.


The ideas in this website are not intended as a substitute for the advice of a trained health professional. All matters regarding your health require medical supervision. Consult your physician and/or health care professional before adopting any nutritional, exercise, or medical protocol. Consult your physician about any condition that may require diagnosis or medical attention. Statements regarding certain products and services represent the views of the author alone, and do not constitute a recommendation or endorsement or any product or service.